Sunami Takeshi, Tauchi Jun, Sakashita Katsuya, Yukimoto Kiyotaka, Sawada Ryugo, Sakamoto Kazutsugu
Dept. of Surgery, Izumi Municipal Hospital.
Gan To Kagaku Ryoho. 2014 May;41(5):649-51.
We present a case of recurrent gastric cancer in which stable disease status was achieved for four months due to treatment with capecitabine/cisplatin (CDDP)after the failure of multiple anticancer drugs including S-1/CDDP. A 67-year-old man was diagnosed with multiple liver metastases one year after distal gastrectomy+D2 dissection for gastric cancer. S-1/CDDP was given as the first-line treatment, followed by paclitaxel (PTX), irinotecan (CPT-11), and docetaxel (DOC). The tumor in the anterior segment of the liver was resistant to all of these chemotherapies except for PTX, which is why the regimens were changed. However, this tumor shrank and achieved stable disease status for four months after capecitabine/CDDP therapy given as fifth-line treatment. Our case suggests that S-1 and capecitabine do not always exhibit cross-resistance. Therefore, capecitabine may be effective in S-1-pretreated patients, and vice versa.
我们报告一例复发性胃癌病例，该患者在包括S-1/顺铂（CDDP）在内的多种抗癌药物治疗失败后，接受卡培他滨/顺铂（CDDP）治疗，病情稳定达四个月。一名67岁男性在远端胃癌根治术+D2淋巴结清扫术后一年被诊断为多发肝转移。一线治疗给予S-1/CDDP，随后依次使用紫杉醇（PTX）、伊立替康（CPT-11）和多西他赛（DOC）。肝脏前段的肿瘤对除PTX外的所有这些化疗均耐药，因此更改了治疗方案。然而，在作为第五线治疗给予卡培他滨/CDDP治疗后，该肿瘤缩小并实现了四个月的病情稳定。我们的病例表明，S-1和卡培他滨并不总是表现出交叉耐药性。因此，卡培他滨可能对接受过S-1预处理的患者有效，反之亦然。
